Ceva Animal Health, a global leader in animal health and the world’s fifth-largest animal health company, has announced a significant restructuring of its shareholding. The move aims to accelerate its growth by bringing in new investors while solidifying partnerships with existing long-term stakeholders.
The restructuring sees Ceva’s current investors, including the “Friends of Ceva” group and key players such as the Singapore-based global investment firm Temasek, reaffirming their confidence in the company’s future. Temasek, a leading investor in Ceva, remains at the forefront of the renewed investment, with several other investors, including French firms EMZ and Sagard, Asia’s HOPU Investments, and U.S.-based Continental Grain Company, also renewing their commitments.
In addition to the renewed investments, Ceva is welcoming new investors to fuel its expansion plans. The French-based Mérieux Institute and ARCHIMED, led by veterinarian Dr. Denis Ribon, have joined the latest funding round. ARCHIMED, an investment fund specializing in healthcare, will support Ceva’s efforts to expand internationally and accelerate its research initiatives. The Bettencourt-Meyers family, through investment holding Téthys Invest, and Canadian pension fund PSP Investments have also increased their stakes in the company.
Ceva’s management, under the leadership of CEO Dr. Marc Prikazsky, has also reinforced its own participation in the company. Despite the influx of new investment, Ceva remains committed to maintaining its independence, with its management retaining the majority of voting rights.
With a workforce of 7,000 employees, Ceva operates in 47 countries and is a key player in the animal health sector, particularly in veterinary vaccines. Its products, services, and equipment are distributed globally, serving veterinarians, livestock professionals, and pet owners.
Founded in 1999, Ceva has experienced remarkable growth, with revenues increasing fourteenfold to €1.77 billion last year. The company is known for its commitment to innovation, having developed the first nucleotide vaccine for veterinary use and pioneering gene therapy for companion animals. Ceva is also dedicated to environmental sustainability and the preservation of animal biodiversity as part of its broader corporate responsibility.
The company’s strategic investment partnerships are designed to further strengthen its position as a global leader in animal health, ensuring continued growth and innovation in the years to come.
Related topics
